Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications

Ann Neurol. 2015 Nov;78(5):824-30. doi: 10.1002/ana.24481. Epub 2015 Aug 25.

Abstract

Clinical classification of early dementia and mild cognitive impairment (MCI) is imprecise. We reported previously that molecular imaging classification of early dementia and MCI with dual amyloid and dopamine terminal positron emission tomography differs significantly from expert clinical classification. We now report pathological diagnoses in a substantial subset of our previously imaged subjects. Among 36 subjects coming to autopsy, imaging classifications and pathological diagnosis were concordant in 33 cases (κ = 0.85). This approach enhanced specificity of Alzheimer's disease diagnosis. The strong concordance of imaging-based classifications and pathological diagnoses suggests that this imaging approach will be useful in establishing more accurate and convenient classification biomarkers for dementia research.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / diagnostic imaging
  • Amyloid / metabolism*
  • Autopsy
  • Biomarkers
  • Cognitive Dysfunction / diagnostic imaging
  • Dementia / classification*
  • Dementia / diagnostic imaging*
  • Dopamine / metabolism*
  • Female
  • Humans
  • Lewy Body Disease / pathology
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Parietal Lobe / pathology
  • Positron-Emission Tomography
  • TDP-43 Proteinopathies / pathology

Substances

  • Amyloid
  • Biomarkers
  • Dopamine